BAYER/HOECHST PHASE II REVERSE TRANSCRIPTASE INHIBITOR TRIAL EXPECTED TO BEGIN IN AUGUST; PARTNERS SOUGHT FOR COMBO THERAPY IN HIV -- BAYER R&D BRIEFING
Executive Summary
Bayer and Hoechst plan to begin Phase II clinical testing in August of HBY-097, the first candidate to emerge from the companies' AIDS research collaboration.